USA - NYSE:DGX - US74834L1008 - Common Stock
The current stock price of DGX is 186.85 USD. In the past month the price decreased by -0.27%. In the past year, price increased by 16.46%.
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| CVS | CVS HEALTH CORP | 11.72 | 101.80B | ||
| CI | THE CIGNA GROUP | 9.53 | 72.23B | ||
| LH | LABCORP HOLDINGS INC | 16.81 | 22.10B | ||
| BTSGU | BRIGHTSPRING HEALTH SERV - BTSG 6 3/4 02/01/27 | 112.65 | 20.35B | ||
| GH | GUARDANT HEALTH INC | N/A | 12.20B | ||
| HIMS | HIMS & HERS HEALTH INC | 72.26 | 8.82B | ||
| DVA | DAVITA INC | 13.39 | 8.84B | ||
| CHE | CHEMED CORP | 20.34 | 6.52B | ||
| RDNT | RADNET INC | 195.92 | 5.73B | ||
| BTSG | BRIGHTSPRING HEALTH SERVICES | 32.98 | 5.96B | ||
| OPCH | OPTION CARE HEALTH INC | 19.49 | 4.71B | ||
| WGS | GENEDX HOLDINGS CORP | 72.57 | 3.92B |
Quest Diagnostics, Inc. engages in the provision of diagnostic testing, information, and services. The company is headquartered in Secaucus, New Jersey and currently employs 45,000 full-time employees. The firm provides diagnostic insights from the results of its laboratory testing to enable people, physicians, and organizations to take action to improve health outcomes. The company operates through the DIS segment, which provides diagnostic information services to a range of customers within its primary customer channels: physicians, hospitals, and patients and consumers. The company offers broad access to clinical testing through a nationwide network of laboratories, patient service centers, phlebotomists in physician offices, and connectivity resources, including call centers and mobile phlebotomists, nurses and other health and wellness professionals. The company also focuses on artificial intelligence (AI) and digital pathology solutions. The Company’s services primarily are provided under the Quest Diagnostics brand and under other brands, including AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum.
QUEST DIAGNOSTICS INC
500 Plaza Drive
Secaucus NEW JERSEY 07094 US
CEO: Stephen H. Rusckowski
Employees: 50500
Phone: 19735202700
Quest Diagnostics, Inc. engages in the provision of diagnostic testing, information, and services. The company is headquartered in Secaucus, New Jersey and currently employs 45,000 full-time employees. The firm provides diagnostic insights from the results of its laboratory testing to enable people, physicians, and organizations to take action to improve health outcomes. The company operates through the DIS segment, which provides diagnostic information services to a range of customers within its primary customer channels: physicians, hospitals, and patients and consumers. The company offers broad access to clinical testing through a nationwide network of laboratories, patient service centers, phlebotomists in physician offices, and connectivity resources, including call centers and mobile phlebotomists, nurses and other health and wellness professionals. The company also focuses on artificial intelligence (AI) and digital pathology solutions. The Company’s services primarily are provided under the Quest Diagnostics brand and under other brands, including AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum.
The current stock price of DGX is 186.85 USD. The price decreased by -1.06% in the last trading session.
QUEST DIAGNOSTICS INC (DGX) has a dividend yield of 1.81%. The yearly dividend amount is currently 2.98.
DGX has a ChartMill Technical rating of 5 out of 10 and a ChartMill Fundamental rating of 5 out of 10.
QUEST DIAGNOSTICS INC (DGX) operates in the Health Care sector and the Health Care Providers & Services industry.
The next ex-dividend date for QUEST DIAGNOSTICS INC (DGX) is October 3, 2025.
QUEST DIAGNOSTICS INC (DGX) has a market capitalization of 20.89B USD. This makes DGX a Large Cap stock.
ChartMill assigns a technical rating of 5 / 10 to DGX. When comparing the yearly performance of all stocks, DGX turns out to be only a medium performer in the overall market: it outperformed 69.14% of all stocks.
ChartMill assigns a fundamental rating of 5 / 10 to DGX. While DGX belongs to the best of the industry regarding profitability, there are some minor concerns on its financial health.
Over the last trailing twelve months DGX reported a non-GAAP Earnings per Share(EPS) of 9.76. The EPS increased by 10.41% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 8.88% | ||
| ROA | 5.95% | ||
| ROE | 13.27% | ||
| Debt/Equity | 0.71 |
24 analysts have analysed DGX and the average price target is 200.6 USD. This implies a price increase of 7.36% is expected in the next year compared to the current price of 186.85.
For the next year, analysts expect an EPS growth of 9.8% and a revenue growth 11.72% for DGX